KR20030051802A - Nutritional composition for an immune condition - Google Patents
Nutritional composition for an immune condition Download PDFInfo
- Publication number
- KR20030051802A KR20030051802A KR10-2003-7006389A KR20037006389A KR20030051802A KR 20030051802 A KR20030051802 A KR 20030051802A KR 20037006389 A KR20037006389 A KR 20037006389A KR 20030051802 A KR20030051802 A KR 20030051802A
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- composition
- composition according
- calcium
- zinc
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 235000016709 nutrition Nutrition 0.000 title abstract description 27
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 20
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241000894006 Bacteria Species 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 10
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 10
- 229960000304 folic acid Drugs 0.000 claims abstract description 10
- 235000019152 folic acid Nutrition 0.000 claims abstract description 10
- 239000011724 folic acid Substances 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004310 lactic acid Substances 0.000 claims abstract description 10
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 10
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 10
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 10
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 10
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 10
- 239000011701 zinc Substances 0.000 claims abstract description 10
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 10
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000010949 copper Substances 0.000 claims abstract description 8
- 229910052802 copper Inorganic materials 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000011669 selenium Substances 0.000 claims abstract description 8
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 8
- 229920001202 Inulin Polymers 0.000 claims abstract description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 7
- 229940029339 inulin Drugs 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 235000013376 functional food Nutrition 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 235000015097 nutrients Nutrition 0.000 claims description 20
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 18
- 239000011707 mineral Substances 0.000 claims description 18
- 235000010755 mineral Nutrition 0.000 claims description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- 229910052791 calcium Inorganic materials 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- 229930003316 Vitamin D Natural products 0.000 claims description 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 229960002477 riboflavin Drugs 0.000 claims description 6
- 229960003495 thiamine Drugs 0.000 claims description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 6
- 235000019155 vitamin A Nutrition 0.000 claims description 6
- 239000011719 vitamin A Substances 0.000 claims description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims description 6
- 239000011691 vitamin B1 Substances 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 235000019166 vitamin D Nutrition 0.000 claims description 6
- 239000011710 vitamin D Substances 0.000 claims description 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 6
- 229940045997 vitamin a Drugs 0.000 claims description 6
- 229940046008 vitamin d Drugs 0.000 claims description 6
- 229960003284 iron Drugs 0.000 claims description 4
- 229940091250 magnesium supplement Drugs 0.000 claims description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 239000005060 rubber Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 2
- 241000220479 Acacia Species 0.000 claims 1
- 230000001420 bacteriolytic effect Effects 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 241000186660 Lactobacillus Species 0.000 abstract 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract 1
- 229940107187 fructooligosaccharide Drugs 0.000 abstract 1
- 229940039696 lactobacillus Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 10
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 230000035764 nutrition Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108010010256 Dietary Proteins Proteins 0.000 description 3
- 102000015781 Dietary Proteins Human genes 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 235000021245 dietary protein Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000006180 nutrition needs Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000021076 total caloric intake Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000020509 fortified beverage Nutrition 0.000 description 1
- 235000020189 fortified milk Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 235000021084 monounsaturated fats Nutrition 0.000 description 1
- 235000020783 nutrient-dense food Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 235000021580 ready-to-drink beverage Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000019527 sweetened beverage Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/244—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
면역 상태의 예방 또는 치료를 위한 영양 조성물이 기술된다. 넓은 의미로, 이는 적어도 비타민 E, 비타민 C, 비타민 B6, 엽산, 비타민 B12, 구리, 아연, 셀레늄, 프룩토올리고당 및/또는 이눌린, 균활성 젖산 박테리아를 함유한다. 예를 들어, 한 구현예에서 이는 300 g 당 150 IU 비타민 E, 120 ㎎ 비타민 C, 2 ㎎ 비타민 B6, 400 ㎍ 엽산, 3.8 ㎍ 비타민 B12, 1.5 ㎎ 구리, 15 ㎎ 아연, 1000 ㎍ 셀레늄, 3 g 프룩토올리고당 및/또는 이눌린, 10 E10 cfu ST11 락토바실루스를 함유한다. 이의 제조 방법; 기능성 식품 또는 의약의 제조에서의 이의 용도; 및 유효량의 조성물을 투여하는 것을 포함하는 면역 상태의 예방 또는 치료 방법이 기술된다.Nutritional compositions for the prevention or treatment of an immune condition are described. In a broad sense, it contains at least vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc, selenium, fructooligosaccharides and / or inulin, a bactericidal lactic acid bacterium. For example, in one embodiment it is 150 IU vitamin E per 300 g, 120 mg vitamin C, 2 mg vitamin B6, 400 μg folic acid, 3.8 μg vitamin B12, 1.5 mg copper, 15 mg zinc, 1000 μg selenium, 3 g Fructooligosaccharide and / or inulin, 10 E10 cfu ST11 lactobacillus. Its preparation method; Its use in the manufacture of functional foods or medicaments; And methods for preventing or treating an immune condition comprising administering an effective amount of the composition.
Description
본 발명은 면역 상태의 예방 또는 치료를 위한 영양 조성물, 조성물의 제조 방법, 면역 상태의 예방 또는 치료를 위한 기능성 식품 또는 의약의 제조에서의 조성물의 용도, 및 유효량의 조성물을 투여하는 것을 포함하는 면역 상태의 치료 방법에 관한 것이다.The present invention provides a nutritional composition for the prevention or treatment of an immune condition, a method of making the composition, the use of the composition in the manufacture of a functional food or medicament for the prevention or treatment of an immune condition, and an immune comprising administering an effective amount of the composition A method for treating a condition.
본 명세서에서, 용어 "함유한다"는 "특히 포함한다"를 의미한다. 이는 "단지 구성된다"는 것으로 해석되지 않는다.As used herein, the term "contains" means "including in particular." It is not to be interpreted as "only constructed".
본 명세서에서, 용어 "면역 상태"는 손상된 면역 반응, 염증 상태, 염증, 만성 질환 (예를 들어 관절염 또는 위염), 노화와 관련되어 염증성 반응의 증가에 이르는 상태로 구성되는 군으로부터 선택되는 병을 나타낸다.As used herein, the term “immune condition” refers to a disease selected from the group consisting of impaired immune response, inflammatory condition, inflammation, chronic disease (eg arthritis or gastritis), a condition leading to an increase in inflammatory response associated with aging. Indicates.
65 세 이상의 미국인은 전환기에 US 인구의 4 % 이상을 차지하였다; 현재, 이들은 인구의 12 % 이상을 초과한다. 그러나, 이들은 US 인구의 12 %를 차지하지만, 급성 병상 기간의 40 % 이상을 차지하고, 모든 처방 약물의 30 % 이상을 구입하며, US 보건 예산의 30 %를 소비한다. 또한, 2030년에는 7천만명의 미국인 (1:5)이 65세 이상일 것으로 추정되고, 85세 이상은 모든 연령군의 가장 높은 백분율 증가를 경험할 것으로 예상된다.Americans age 65 and older accounted for over 4% of the US population at the transition; At present, they exceed more than 12% of the population. However, they account for 12% of the US population, but account for more than 40% of acute beds, purchase more than 30% of all prescription drugs, and consume 30% of the US health budget. It is also estimated that 70 million Americans (1: 5) will be 65 or older by 2030, and those over 85 are expected to experience the highest percentage increase in all age groups.
인구의 평균 연령이 증가하면서, 영양적인 요구 및 치료와 관련된 노화의 독특한 면모를 더 잘 이해하는 것이 필수적이다. 많은 생리학적 기능이 성인 일생에 걸쳐 점진적으로 쇠퇴하고, 영양에 영향을 준다. 예를 들어, 기능 세포수에서의 감소 및 결과적인 대사 과정의 감속으로 중장년층에서 칼로리 요구량이 저하된다. 또한, 노화에 일반적으로 수반되는 신체 활동에서의 감소는 에너지 요구량을 추가로 저하시킨다. 중장년층 환자의 전체 칼로리 섭취를 단지 감소시키는 것은 이들의 요구되는 영양에 역효과를 미칠 수 있다. 전체 칼로리 섭취가 감소될 때, 남아있는 식품 섭취에서 단백질, 비타민 및 미네랄이 적절하게 균형되어 섭취되도록 주의하여여 한다. 중장년층에서 칼로리 섭취를 감소시키기 위해, "엠프티(empty)" 칼로리 (즉, 지방)의 소비는 감소될 수 있고, 고영양(nutrient-dense) 식품 (즉, 탄수화물 및 단백질)의 소비는 증가될 수 있다.As the average age of the population increases, it is essential to better understand the unique aspects of aging associated with nutritional needs and treatment. Many physiological functions gradually decline and affect nutrition throughout adult life. For example, the reduction in functional cell numbers and the resulting slowdown of metabolic processes lower the calorie requirement in the elderly. In addition, the reduction in physical activity normally associated with aging further lowers energy requirements. Only reducing the total calorie intake of older patients can adversely affect their required nutrition. When the total calorie intake is reduced, care should be taken to ensure that the protein, vitamins and minerals are properly balanced in the remaining food intake. To reduce calorie intake in the elderly, the consumption of “empty” calories (ie, fat) can be reduced, and consumption of high nutrient-dense foods (ie, carbohydrates and proteins) can be increased. Can be.
중년기의 영양 요구량이 성인의 것과 상이하지만, 건강 관리 환경에서, 표준 영양 제형물은 현재 사용되는 성분 영양의 1차 형태이다. 물론, 표준 제형물은 중장년층 환자의 영양 요구량을 고려하지 않는다. 표준 제품에는 중장년층 환자의 통상적인 결핍 및 대사 변화를 보완하기 위해 주요 미량영양소가 보충되어야 한다는 문제가 있다. 따라서, 중장년층 환자의 영양 요구량을 충족시키는 영양 조성물이 필요하다.Although middle age nutritional requirements differ from those of adults, in a health care environment, standard nutritional formulations are the primary form of ingredient nutrition currently used. Of course, the standard formulation does not take into account the nutritional needs of older patients. Standard products have the problem that major micronutrients must be replenished to compensate for the usual deficiencies and metabolic changes in older patients. Accordingly, there is a need for nutritional compositions that meet the nutritional needs of elderly patients.
상기 문제에 더하여, 중장년층에서 뿐만 아니라 임상 및 작업(performance) 환경에서, 예를 들어, 손상으로부터의 운동선수의 회복과 관련되어, 면역 상태의 문제를 다루기 위한 조성물이 요구된다.In addition to the above problems, there is a need for compositions to address the problem of immune status, as well as in the clinical and performance environment, for example, in relation to the recovery of athletes from injury.
또한, 식이요법 및 영양 보충제의 효과가 생존 및 삶의 질을 개선시키는데 기능할 수 있다는 것이 알려져 있다. 특히, 건강, 특히 면역 상태와 관련된 건강을 개선시킬 수 있는 영양 조성물이 필요하다.It is also known that the effects of diet and nutritional supplements can function to improve survival and quality of life. In particular, there is a need for nutritional compositions that can improve health, particularly health associated with immune conditions.
또한, 손상된 면역 반응의 문제가 노화, 만성 병리학적 상태 및/또는 영양실조와 관련될 수 있다는 것이 알려져 있다. 이러한 문제는 영양 보충제를 제공함으로써 부분적으로 다루어졌다. 그러나, 이러한 보충제들에는 이들이, 일반적으로, 특정 병에 특이적이고, 상태가 더욱 복잡하게 조합된 환자에게 양호한 영양 지원을 제공하지 않는다는 문제가 있다. 이는 중장년층 환자에 특히 관련된다. 게다가, 나이가 들면서 관절염, 위염 등과 같은 만성 질환의 가능성이 증가하여, 염증성 반응이 증가한다.It is also known that problems with impaired immune responses may be associated with aging, chronic pathological conditions and / or malnutrition. This problem has been addressed in part by providing nutritional supplements. However, these supplements have the problem that they generally do not provide good nutritional support to patients who are specific to a particular disease and have a more complex combination of conditions. This is particularly relevant for elderly patients. In addition, with age, the likelihood of chronic diseases such as arthritis, gastritis increases, and the inflammatory response increases.
또한, 전염성 설사 (로타바이러스 및 박테리아성 감염), 알레르기, 내장 완전성의 수복 및 유지, 박테리아 과성장, 내독혈증 및 장 침투성과 관련된 문제를 다루는 영양 조성물이 필요하다.There is also a need for nutritional compositions that address issues related to infectious diarrhea (rotavirus and bacterial infection), allergies, repair and maintenance of visceral integrity, bacterial overgrowth, endotoemia and intestinal permeability.
본 발명은 상기 제시된 문제들을 다룬다.The present invention addresses the problems presented above.
놀랍게도, 중장년층 환자에게 영양을, 뿐만 아니라 예를 들어 운동선수에게 작업 영양을, 또는 병원 환자에게 임상 영양을 제공하는데 사용될 수 있는 조성물을 발견하였다.Surprisingly, a composition has been found that can be used to provide nutrition for elderly patients, as well as for example, nutrition for athletes, or clinical nutrition for hospital patients.
따라서, 제 1 양상에서, 본 발명은 단백질 공급원, 탄수화물 공급원, 지방 공급원, 균활성 젖산 박테리아 및 추가적으로 프룩토올리고당 및/또는 이눌린을 함유하는 조성물을 제공한다.Thus, in a first aspect, the present invention provides a composition containing a protein source, a carbohydrate source, a fat source, a fungal lactic acid bacterium and additionally fructooligosaccharides and / or inulin.
제 2 양상에서, 본 발명은 필요한 영양소를 필요한 양으로 함께 배합하는 단계를 포함하는, 본 발명의 구현예에 따른 조성물의 제조 방법을 제공한다.In a second aspect, the present invention provides a method of preparing a composition according to an embodiment of the present invention, comprising combining the necessary nutrients together in the required amount.
제 3 양상에서, 본 발명은 면역 상태의 예방 또는 치료에서의 본 발명에 따른 조성물의 용도를 제공한다.In a third aspect, the present invention provides the use of a composition according to the invention in the prevention or treatment of an immune condition.
제 4 양상에서, 본 발명은 면역 상태의 예방 또는 치료를 위한 기능성 식품 또는 의약의 제조에서의 본 발명의 구현예에 따른 조성물의 용도를 제공한다.In a fourth aspect, the present invention provides the use of a composition according to an embodiment of the present invention in the manufacture of a functional food or medicament for the prevention or treatment of an immune condition.
제 5 양상에서, 본 발명은 유효량의 본 발명의 구현예에 따른 조성물을 투여하는 것을 포함하는, 면역 상태의 예방 또는 치료 방법을 제공한다.In a fifth aspect, the invention provides a method of preventing or treating an immune condition comprising administering an effective amount of a composition according to an embodiment of the invention.
바람직하게는, 본 발명에 따른 조성물의 구현예는 비타민 E, 비타민 C, 비타민 B6, 엽산, 비타민 B12, 구리, 아연 및 셀레늄으로 구성되는 군으로부터 선택되는 하나 이상의 영양소 또는 미네랄을 함유한다. 더욱 바람직하게는, 2 개 이상의 이러한 영양소 또는 미네랄을 함유한다. 더욱 더 바람직하게는, 3 개 이상의 이러한 영양소 또는 미네랄을 함유한다. 가장 바람직하게는, 모든 이러한 미네랄 또는 영양소를 함유한다.Preferably, embodiments of the compositions according to the invention contain at least one nutrient or mineral selected from the group consisting of vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc and selenium. More preferably, it contains two or more such nutrients or minerals. Even more preferably, it contains three or more such nutrients or minerals. Most preferably it contains all such minerals or nutrients.
바람직하게는, 본 발명의 따른 조성물의 구현예는 칼슘, 인, 마그네슘, 철, 비타민 A, 비타민 B1, 비타민 B2, 니아신 및 비타민 D로 구성되는 군으로부터 선택되는 하나 이상의 영양소 또는 미네랄을 추가적으로 함유한다. 더욱 바람직하게는, 2 개 이상의 이러한 영양소 또는 미네랄을 함유한다. 더욱 더 바람직하게는, 3 개 이상의 이러한 영양소 또는 미네랄을 함유한다. 가장 바람직하게는, 본 발명의 따른 조성물의 구현예는 모든 이러한 미네랄 또는 영양소를 함유한다.Preferably, embodiments of the compositions according to the invention additionally contain at least one nutrient or mineral selected from the group consisting of calcium, phosphorus, magnesium, iron, vitamin A, vitamin B1, vitamin B2, niacin and vitamin D. . More preferably, it contains two or more such nutrients or minerals. Even more preferably, it contains three or more such nutrients or minerals. Most preferably, embodiments of the compositions according to the invention contain all such minerals or nutrients.
바람직하게는, 본 발명에 따른 조성물의 구현예는 밀크 칼슘, 또는 밀크 칼슘으로부터 유래된 칼슘의 형태인 칼슘을 함유한다.Preferably, embodiments of the compositions according to the invention contain calcium in the form of milk calcium, or calcium derived from milk calcium.
바람직하게는, 본 발명에 따른 조성물의 구현예는 파라카제이(paracasei) 및 존스니이(johnsonii) 박테리아로 구성되는 군으로부터 선택되는 하나 이상의 균활성 젖산 박테리아를 함유한다. 더욱 바람직하게는, 본 발명에 따른 조성물의 구현예는 ST11 (명칭 NCCMI-2116으로 기탁됨) 및 La1 (명칭 NCCMI-1225로 기탁됨)으로 구성되는 군으로부터 선택되는 하나 이상의 균활성 젖산 박테리아를 함유한다.Preferably, an embodiment of the composition according to the invention contains at least one bactericidal lactic acid bacterium selected from the group consisting of paracasei and johnsonii bacteria. More preferably, embodiments of the compositions according to the invention contain at least one bacteriostatic lactic acid bacterium selected from the group consisting of ST11 (named NCCMI-2116) and La1 (named NCCMI-1225). do.
바람직하게는, 본 발명에 따른 조성물의 구현예는 조성물 300 g 당 하기 질량 또는 양의 영양소 또는 미네랄 (존재한다면)을 함유한다. 바람직하게는 이는 1일 당 투여되는 조성물의 양이다.Preferably, embodiments of the composition according to the invention contain the following mass or amount of nutrients or minerals (if present) per 300 g of the composition. Preferably this is the amount of composition administered per day.
비타민 E: 바람직하게는 약 1 IU 내지 약 400 IU, 가장 바람직하게는 약 120 IUVitamin E: preferably about 1 IU to about 400 IU, most preferably about 120 IU
비타민 C: 바람직하게는 약 6 ㎎ 내지 약 300 ㎎, 가장 바람직하게는 약 120 ㎎Vitamin C: preferably about 6 mg to about 300 mg, most preferably about 120 mg
비타민 B6: 바람직하게는 약 0.17 ㎎ 내지 약 3 ㎎, 가장 바람직하게는 약 2 ㎎Vitamin B6: preferably about 0.17 mg to about 3 mg, most preferably about 2 mg
엽산: 바람직하게는 약 40 ㎍ 내지 약 800 ㎍, 가장 바람직하게는 약 400 ㎍Folic acid: preferably about 40 μg to about 800 μg, most preferably about 400 μg
비타민 B12: 바람직하게는 약 0.24 ㎎ 내지 약 5 ㎎, 가장 바람직하게는 약 3.8 ㎍Vitamin B12: preferably about 0.24 mg to about 5 mg, most preferably about 3.8 μg
구리: 바람직하게는 약 0.3 ㎎ 내지 약 3 ㎎, 가장 바람직하게는 약 1.5 ㎎Copper: preferably about 0.3 mg to about 3 mg, most preferably about 1.5 mg
아연: 바람직하게는 약 1.5 ㎎ 내지 약 15 ㎎, 가장 바람직하게는 약 15 ㎎Zinc: preferably about 1.5 mg to about 15 mg, most preferably about 15 mg
셀레늄: 바람직하게는 약 7 ㎍ 내지 약 300 ㎍, 가장 바람직하게는 약 100 ㎍Selenium: preferably about 7 μg to about 300 μg, most preferably about 100 μg
프룩토올리고당 및/또는 아카시아 고무: 바람직하게는 약 4 g 내지 약 50 g, 가장 바람직하게는 약 6 gFructooligosaccharides and / or acacia rubbers: preferably about 4 g to about 50 g, most preferably about 6 g
젖산 박테리아: 바람직하게는 약 10 E8 내지 약 10 E12 cfu. 가장 바람직하게는 약 10 E10 cfu.Lactic acid bacteria: preferably from about 10 E8 to about 10 E12 cfu. Most preferably about 10 E10 cfu.
바람직하게는, 본 발명에 따른 조성물의 구현예는 조성물 300 g 당 하기 질량 또는 양의 영양소 또는 미네랄 (존재한다면)로부터 선택되는 하나 이상의 영양소를 함유한다. 바람직하게는, 이는 1일 당 투여되는 조성물의 양이다.Preferably, embodiments of the compositions according to the invention contain one or more nutrients selected from the following mass or amounts of nutrients or minerals (if present) per 300 g of the composition. Preferably, this is the amount of composition administered per day.
칼슘: 약 100 ㎎ 내지 약 300 ㎎, 더욱 바람직하게는 약 200 ㎎;Calcium: about 100 mg to about 300 mg, more preferably about 200 mg;
인: 약 50 ㎎ 내지 약 615 ㎍, 더욱 바람직하게는 약 150 ㎎;Phosphorus: about 50 mg to about 615 μg, more preferably about 150 mg;
마그네슘: 약 110 ㎎ 내지 약 210 ㎎, 더욱 바람직하게는 약 60 ㎎;Magnesium: about 110 mg to about 210 mg, more preferably about 60 mg;
비타민 A: 약 1000 IU 내지 약 1500 IU, 더욱 바람직하게는 약 1333 IU;Vitamin A: about 1000 IU to about 1500 IU, more preferably about 1333 IU;
비타민 D: 약 50 IU 내지 약 150 IU, 더욱 바람직하게는 약 100 IU;Vitamin D: from about 50 IU to about 150 IU, more preferably about 100 IU;
비타민 E: 약 5.0 IU 내지 약 150 IU, 더욱 바람직하게는 약 120 IU;Vitamin E: about 5.0 IU to about 150 IU, more preferably about 120 IU;
비타민 C: 약 30 ㎎ 내지 약 500 ㎎, 더욱 바람직하게는 약 120 ㎎;Vitamin C: about 30 mg to about 500 mg, more preferably about 120 mg;
비타민 B1: 약 0.1 ㎎ 내지 약 2 ㎎, 더욱 바람직하게는 약 0.25 ㎎;Vitamin B1: about 0.1 mg to about 2 mg, more preferably about 0.25 mg;
비타민 B2: 약 0.1 ㎎ 내지 약 0.6 ㎎, 더욱 바람직하게는 약 0.3 ㎎;Vitamin B2: about 0.1 mg to about 0.6 mg, more preferably about 0.3 mg;
니아신: 약 1.5 ㎎ 내지 약 7.2 ㎎, 더욱 바람직하게는 약 3 ㎎;Niacin: about 1.5 mg to about 7.2 mg, more preferably about 3 mg;
비타민 B6: 약 1.0 ㎎ 내지 약 3.0 ㎎, 더욱 바람직하게는 약 2 ㎎;Vitamin B6: about 1.0 mg to about 3.0 mg, more preferably about 2 mg;
엽산: 약 200 ㎍ 내지 약 600 ㎍, 더욱 바람직하게는 약 400 ㎍;Folic acid: about 200 μg to about 600 μg, more preferably about 400 μg;
비타민 B12: 약 1.5 ㎍ 내지 약 4.5 ㎍, 더욱 바람직하게는 약 3.8 ㎍;Vitamin B12: about 1.5 μg to about 4.5 μg, more preferably about 3.8 μg;
철: 약 2.0 ㎎ 내지 약 5 ㎎, 더욱 바람직하게는 2.75 ㎎; 및Iron: about 2.0 mg to about 5 mg, more preferably 2.75 mg; And
아연: 약 10 ㎎ 내지 약 20 ㎎, 더욱 바람직하게는 약 15 ㎎.Zinc: about 10 mg to about 20 mg, more preferably about 15 mg.
바람직하게는, 본 발명에 따른 조성물의 구현예는 아카시아 고무를 함유한다.Preferably, embodiments of the composition according to the invention contain acacia rubber.
바람직하게는, 본 발명에 따른 방법의 구현예는 영양소들을 필요한 양으로 배합하고 배합된 혼합물을 압출하는 단계를 포함한다. 더욱 바람직하게는, 혼합물을 분무 건조시키는 것을 포함한다.Preferably, an embodiment of the method according to the invention comprises combining the nutrients in the required amount and extruding the blended mixture. More preferably, spray drying the mixture.
본 발명의 장점은 즉석에서 물에 용해되어 음료 또는 수프를 제공할 수 있는 영양 조성물을 제공한다는 것이다. 이는 조리를 필요로 하지 않는다.An advantage of the present invention is that it provides a nutritional composition which can be readily dissolved in water to provide a beverage or soup. It does not require cooking.
본 발명의 또다른 장점은 면역 상태의 예방 또는 치료를 위해 식품에 개조되어 단순히 투여될 수 있는 단일 조성물을 제공한다는 것이다. 조성물은 임상 또는 작업 영양 환경에서 제공될 수 있고, 특히 중장년층 환자에 적절하다.Another advantage of the present invention is that it provides a single composition that can be modified and simply administered to food for the prevention or treatment of an immune condition. The composition may be provided in a clinical or occupational nutrition setting, and is particularly suitable for elderly patients.
균활성 박테리아에 의해 제공되는 장점은 병원성 박테리아에 의해 야기되는 설사의 예방 또는 저해; 로타바이러스에 의한 설사, 특히 장세포 감염의 예방 또는 저해; 설사를 야기하는 병원성 박테리아에 의한 장의 콜로니화의 저해; 및 숙주 생물의 장 점막에 부착하여 콜로니화시키는 능력이 포함된다.Advantages offered by fungal bacteria include the prevention or inhibition of diarrhea caused by pathogenic bacteria; Prevention or inhibition of diarrhea by rotavirus, particularly enteric cell infection; Inhibition of intestinal colonization by pathogenic bacteria causing diarrhea; And the ability to attach and colonize the intestinal mucosa of the host organism.
본 발명의 또다른 장점은 당뇨병에 이로운 조성물을 제공한다는 것이다. 이는 낮은 혈당 지수를 제공하는 다량영양소, 단백질, 탄수화물 및 지방의 특정 조성에 기인한다.Another advantage of the present invention is that it provides a composition that is beneficial to diabetes. This is due to the specific composition of macronutrients, proteins, carbohydrates and fats that provide low glycemic index.
본 발명의 추가적인 특징 및 장점은 하기 제공되는 현재 바람직한 구현예의상세한 설명에 기술되고, 이로부터 명백해질 것이다.Additional features and advantages of the invention will be described in and will become apparent from the detailed description of the presently preferred embodiments provided below.
명쾌함 및 간결한 기술을 위해, 동일한 또는 별도의 구현예의 일부로서 특징들이 본원에 기술되지만, 본 발명의 범주에는 모든 또는 일부 기술된 특징들이 조합된 구현예가 포함될 수 있다는 것이 명백할 것이다.For clarity and concise description, features are described herein as part of the same or separate embodiments, but it will be apparent that the scope of the invention may include embodiments in which all or some of the described features are combined.
한 구현예에서, 영양 조성물은 단백질 공급원을 함유한다. 단백질 공급원은 바람직하게는 영양 제형물의 에너지의 약 5 % 내지 약 55 %를 제공한다; 예를 들어 에너지의 약 20 % 내지 약 50 %, 바람직하게는 약 26 %. 식이 단백질이 단백질 공급원으로 바람직하다. 식이 단백질은 임의의 적절한 식이 단백질일 수 있다; 예를 들어, 동물성 단백질 (예컨대 밀크 단백질, 육류 단백질 또는 난 단백질); 식물성 단백질 (예컨대 대두 단백질, 밀 단백질, 쌀 단백질, 및 완두콩 단백질); 유리 아미노산의 혼합물; 또는 이들의 조합물. 밀크 단백질 예컨대 카제인, 유장 단백질 및 대두 단백질이 특히 바람직하다.In one embodiment, the nutritional composition contains a protein source. The protein source preferably provides about 5% to about 55% of the energy of the nutritional formulation; For example about 20% to about 50% of energy, preferably about 26%. Dietary protein is preferred as a protein source. The dietary protein may be any suitable dietary protein; Animal proteins (such as milk proteins, meat proteins or egg proteins); Vegetable proteins (such as soy protein, wheat protein, rice protein, and pea protein); Mixtures of free amino acids; Or combinations thereof. Milk proteins such as casein, whey protein and soy protein are particularly preferred.
조성물은 탄수화물 공급원 및 지방 공급원을 또한 함유한다.The composition also contains a carbohydrate source and a fat source.
지방 공급원은 바람직하게는 영양 제형물의 에너지의 약 5 % 내지 약 55 %를 제공한다; 예를 들어 에너지의 약 20 % 내지 약 50 %, 바람직하게는 23 %. 지방 공급원을 구성하는 지질은 임의의 적절한 지방 또는 지방 혼합물일 수 있다. 식물성 지방이 특히 적절하다; 예를 들어, 대두유, 팜유, 코코넛유, 홍화유, 해바라기유, 옥수수유, 카놀라유, 레시틴 등. 가장 바람직하게는, 카놀라 및 대두유의 혼합물이다. 동물성 지방 예컨대 밀크 지방 또한 원한다면 첨가될 수 있다.The fat source preferably provides about 5% to about 55% of the energy of the nutritional formulation; For example from about 20% to about 50% of energy, preferably 23%. The lipids constituting the fat source can be any suitable fat or fat mixture. Vegetable fats are particularly suitable; For example, soybean oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil, lecithin and the like. Most preferably, it is a mixture of canola and soybean oil. Animal fats such as milk fat may also be added if desired.
바람직하게는, 조성물은 제품의 전체 에너지의 바람직하게는 약 1 % 내지 약 5 %, 더욱 바람직하게는 2.5 %를 이루는 포화 지방을 함유한다. 바람직하게는, 제품의 전체 에너지의 바람직하게는 약 5 % 내지 약 15 %, 더욱 바람직하게는 약 9.9 %를 이루는 단일불포화 지방을 함유한다. 바람직하게는, 조성물은 제품의 전체 에너지의 바람직하게는 약 5 % 내지 약 15 %, 더욱 바람직하게는 10.1 %를 이루는 다중불포화 지방을 함유한다. 바람직하게는, 조성물은 제품의 전체 에너지의 바람직하게는 약 5 % 내지 약 15 %, 더욱 바람직하게는 8.5 %를 이루는 리놀산을 함유한다. 바람직하게는, 조성물은 제품의 전체 에너지의 바람직하게는 약 0.5 % 내지 약 5 %, 더욱 바람직하게는 1.6 %를 이루는 리놀렌산을 함유한다. 바람직하게는, 리놀산 대 리놀렌산의 비는 약 3 내지 약 8, 더욱 바람직하게는 약 5.3이다.Preferably, the composition contains saturated fats, preferably from about 1% to about 5%, more preferably 2.5% of the total energy of the product. Preferably, it contains monounsaturated fats, preferably from about 5% to about 15%, more preferably about 9.9% of the total energy of the product. Preferably, the composition contains polyunsaturated fats, preferably from about 5% to about 15%, more preferably 10.1% of the total energy of the product. Preferably, the composition contains linoleic acid, which preferably comprises from about 5% to about 15%, more preferably 8.5% of the total energy of the product. Preferably, the composition contains linolenic acid, which preferably comprises from about 0.5% to about 5%, more preferably 1.6% of the total energy of the product. Preferably, the ratio of linoleic acid to linolenic acid is about 3 to about 8, more preferably about 5.3.
탄수화물 공급원은 영양 조성물의 에너지의 약 40 % 내지 약 80 %, 더욱 바람직하게는 약 51 %를 제공한다. 임의의 적절한 탄수화물, 예를 들어, 수크로스, 락토스, 글루코스, 프룩토스, 옥수수 시럽 고형분, 말토덱스트린 또는 이들의 혼합물을 사용할 수 있다.The carbohydrate source provides about 40% to about 80%, more preferably about 51% of the energy of the nutritional composition. Any suitable carbohydrate can be used, such as sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin or mixtures thereof.
조성물의 이러한 구현예는 300 g의 조성물 당 약 10 E10 cfu의 파라카제이 또는 존스니이 균활성 젖산 박테리아 및 약 6 g의 프룩토올리고당 및 이눌린을 추가적으로 함유한다.This embodiment of the composition additionally contains about 10 E10 cfu of paracaze or John's S. fungal lactic acid bacteria and about 6 g of fructooligosaccharides and inulin per 300 g of the composition.
식이 섬유 또한 첨가될 수 있다. 바람직하게는, 식이 섬유는 영양 조성물의 에너지의 약 5 %까지를 제공한다. 식이 섬유는 임의의 적절한 기원, 바람직하게는 프룩토올리고당, 이눌린 또는 이들의 혼합물로부터 유래될 수 있다.Dietary fibers may also be added. Preferably, the dietary fiber provides up to about 5% of the energy of the nutritional composition. Dietary fibers may be derived from any suitable origin, preferably fructooligosaccharides, inulin or mixtures thereof.
추가적인 적절한 비타민 및 미네랄이 상기 기술된 바와 같은 본 발명의 조성물에 함유된다.Further suitable vitamins and minerals are contained in the compositions of the present invention as described above.
모노소듐 글루타메이트가 향미 증강제로서 첨가될 수 있다.Monosodium glutamate may be added as a flavor enhancer.
영양 조성물은 바람직하게는 장내 투여가능하다; 예를 들어, 분말, 액체 농축물, 또는 즉석(ready to drink) 음료의 형태. 분말화 영양 제형물을 제조하기 위해서는, 균질화 혼합물을 적절한 건조 장치 예컨대 분무 건조기 또는 동결 건조기에 옮기고, 분말로 전환시킨다.The nutritional composition is preferably administrable enteric; For example, in the form of a powder, liquid concentrate, or ready to drink beverage. To prepare a powdered nutritional formulation, the homogenization mixture is transferred to a suitable drying apparatus such as a spray dryer or lyophilizer and converted to a powder.
대안적으로, 통상적인 식품을 조성물의 구현예로 보강할 수 있다. 예를 들어, 발효유, 요구르트, 생치즈, 응유 밀크, 과자류의 물품, 예를 들어 가당 음료, 과자 바(bar), 아침식사용 곡류 플레이크 또는 바, 음료수, 밀크 파우더, 대두 기재품, 밀크가 아닌 발효 제품 또는 임상 영양용 영양 보충제. 이어서, 첨가된 조성물의 양은 바람직하게는 약 0.01 중량% 이상이다.Alternatively, conventional foods may be fortified with embodiments of the composition. For example, fermented milk, yoghurt, fresh cheese, curd milk, confectionary products, such as sweetened beverages, snack bars, breakfast cereal flakes or bars, beverages, milk powders, soy products, non-milk Fermented product or nutritional supplement for clinical nutrition. The amount of composition added is then preferably at least about 0.01% by weight.
하기의 실시예는 단지 예시를 위해서 주어지며, 결코 본 발명의 주제를 제한하는 것으로 해석되지 않아야 한다. 백분율 및 부는 달리 언급되지 않는 한 중량 기준이다.The following examples are given for illustrative purposes only and should never be construed as limiting the subject matter of the present invention. Percents and parts are by weight unless otherwise indicated.
실시예 1 및 2: 영양 조성물Examples 1 and 2: Nutritional Composition
필요한 구성성분들을 배합하여 2 개의 영양 조성물을 제조하였다. 이들의 조성을 표 1에 나타낸다. 조성물은 보강된 음료 또는 밀크 제품 디저트를 기초로 1일 당 2개의 경구 보충물의 형태로 소비되도록 의도된다. 전체 1일 용량은 약 300 g 또는 300 ㎎의 조성물이도록 의도된다.Two nutritional compositions were prepared by combining the required ingredients. These compositions are shown in Table 1. The composition is intended to be consumed in the form of two oral supplements per day based on the fortified beverage or milk product dessert. The total daily dose is intended to be about 300 g or 300 mg of the composition.
본원에 기술된 현재 바람직한 구현예의 다양한 변화 및 개질이 당업자에게 명백할 것이라는 것을 이해하여야 한다. 이같은 변화 및 개질은 본 발명의 취지 및 범주를 벗어나지 않으면서, 그리고 이의 부수적인 장점을 손상시키지 않으면서 이루어질 수 있다. 따라서, 이같은 변화 및 개질은 첨부되는 청구항에 의해 커버되는 것으로 의도된다.It should be understood that various changes and modifications of the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the invention and without detracting from its attendant advantages. Accordingly, such changes and modifications are intended to be covered by the appended claims.
Claims (18)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0027761.6A GB0027761D0 (en) | 2000-11-14 | 2000-11-14 | Nutritional composition for an immune condition |
GB0027761.6 | 2000-11-14 | ||
PCT/EP2001/013302 WO2002039834A1 (en) | 2000-11-14 | 2001-11-14 | Nutritional composition for an immune condition |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030051802A true KR20030051802A (en) | 2003-06-25 |
Family
ID=9903140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-7006389A KR20030051802A (en) | 2000-11-14 | 2001-11-14 | Nutritional composition for an immune condition |
Country Status (20)
Country | Link |
---|---|
US (2) | US6929793B2 (en) |
EP (1) | EP1339294B2 (en) |
JP (1) | JP2004513898A (en) |
KR (1) | KR20030051802A (en) |
CN (2) | CN103181564A (en) |
AT (1) | ATE336909T1 (en) |
AU (2) | AU2186002A (en) |
BR (1) | BR0115311A (en) |
CA (1) | CA2427385C (en) |
DE (1) | DE60122570T3 (en) |
ES (1) | ES2269514T5 (en) |
GB (1) | GB0027761D0 (en) |
IL (1) | IL155674A (en) |
MX (1) | MXPA03004268A (en) |
NO (1) | NO326348B1 (en) |
PL (1) | PL201161B1 (en) |
RU (1) | RU2289955C2 (en) |
UA (1) | UA78196C2 (en) |
WO (1) | WO2002039834A1 (en) |
ZA (1) | ZA200304605B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103478716A (en) * | 2013-09-23 | 2014-01-01 | 南昌大学 | Preparation method for functional food with immunity enhancing effect |
KR101388395B1 (en) * | 2008-01-10 | 2014-04-22 | 뉴트리 가부시키가이샤 | Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of elderly |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7029702B2 (en) * | 1998-07-07 | 2006-04-18 | Ritter Natural Sciences Llc | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
ES2311700T3 (en) * | 2002-04-09 | 2009-02-16 | Societe Des Produits Nestle S.A. | LA1 - THE GENOMA OF A LACTOBACILLUS CEPA. |
JP2004059488A (en) * | 2002-07-29 | 2004-02-26 | Asahi Food & Healthcare Ltd | Lactobacillus intestinal disorder controlling composition and food |
EP1530479A2 (en) * | 2002-08-16 | 2005-05-18 | Finzelberg GmbH & Co. KG | Medicament, food supplement, and fodder additive |
GB2395627B (en) * | 2002-11-21 | 2006-05-10 | Hewlett Packard Co | Detector |
ES2364333T3 (en) | 2003-07-15 | 2011-08-31 | Nestec S.A. | NUTRITIVE COMPOSITION LIQUID WITH HIGH FIBER CONTENT AND CALORIC CONTENT FOR THE INTESTINAL HEALTH OF ADVANCED AGES. |
GB0330009D0 (en) | 2003-12-24 | 2004-01-28 | Ferrosan As | Probiotic tablet formulations |
US20050245398A1 (en) * | 2004-04-29 | 2005-11-03 | Healthy Soils, Inc. | Biological composition for enhancing vegetation growth |
US20080126195A1 (en) * | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
US20100233312A9 (en) * | 2005-04-11 | 2010-09-16 | The Procter & Gamble Company | Compositions comprising probiotic and sweetener components |
AU2006296837B2 (en) | 2005-09-28 | 2012-12-13 | Nordic Rebalance A/S | Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors |
ZA200802934B (en) * | 2005-10-06 | 2009-09-30 | Probi Ab | Use of lactobacillus for treatment of virus infections |
JP2009522311A (en) * | 2005-12-29 | 2009-06-11 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Methods for regulating intestinal flora in animals |
CN101384179A (en) * | 2006-02-13 | 2009-03-11 | 麦克内尔营养有限公司 | Lactose-reduced dairy compositions and related methods |
JP2009538614A (en) | 2006-05-28 | 2009-11-12 | シプラ メドプロ リサーチ アンド デヴェロップメント (プロプライエタリー) リミテッド | Probiotic strains and antimicrobial peptides derived therefrom |
US20080038432A1 (en) * | 2006-08-14 | 2008-02-14 | Hoffman Andrew J | Food Additive Comprising at Least One Fiber Source and at Least One Monosaccharide or Sugar Alcohol |
DK1992351T3 (en) | 2007-05-18 | 2016-06-06 | Nestec Sa | Lactobacillus johnsonii for the prevention of post-surgical infection |
WO2009004409A1 (en) * | 2007-06-29 | 2009-01-08 | Sirc - Natural & Dietetic Foods S.R.L. | Preparations contaning microorganisms |
EP2211640A2 (en) * | 2007-09-21 | 2010-08-04 | Kerry Group Services International Limited | A probiotic composition |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
WO2010008491A2 (en) * | 2008-06-25 | 2010-01-21 | Ritter Natural Sciences, Llc | Lactose compositions with decreased lactose content |
US20100004334A1 (en) * | 2008-07-01 | 2010-01-07 | Mead Johnson Nutrition Company | Nutritional Compositions Containing Punicalagins |
BRPI0922511B1 (en) | 2009-01-02 | 2018-07-10 | Nestec S.A. | Food Composition |
US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
SG2014014435A (en) | 2009-02-24 | 2014-07-30 | Ritter Pharmaceuticals Inc | Prebiotic formulations and methods of use |
US20100233347A1 (en) * | 2009-03-13 | 2010-09-16 | Uhrhan Richard B | Food compositions having a realistic meat-like appearance, feel, and texture |
CN101828718B (en) * | 2010-04-29 | 2012-12-26 | 北京世纪劲得保健品有限公司 | High-fiber fruit and vegetable nutrition package and preparation method thereof |
CA2800167A1 (en) | 2010-05-26 | 2011-12-01 | Nestec S.A. | Methods for increasing the production or activity of catalase |
EP2397145A1 (en) * | 2010-06-18 | 2011-12-21 | Nestec S.A. | L. johnsonii La1, B. longum NCC2705 and immune disorders |
US20120015075A1 (en) * | 2010-07-13 | 2012-01-19 | Hero Nutritionals, LLC | Chewable supplement with live microorganisms |
JP6207157B2 (en) * | 2010-09-24 | 2017-10-04 | 株式会社 バイオエルティ | Pharmaceutical composition for treatment and prevention of Th3 march related diseases |
BR112013018839A2 (en) | 2011-01-25 | 2016-09-27 | Nestec Sa | methods and compositions for treating, reducing or preventing deterioration of the visual system of animals |
ES2689225T3 (en) * | 2011-02-07 | 2018-11-12 | Abbott Laboratories | Nutritional products comprising beta-hydroxy-beta-methylbutyrate |
EP2685987B1 (en) | 2011-03-18 | 2019-04-24 | Nestec S.A. | Compositions and methods useful for ameliorating age related maladies |
CA2832234A1 (en) | 2011-04-15 | 2012-10-18 | Nestec S.A. | Methods for regulating sirtuin gene expression |
CN103997899B (en) | 2011-06-20 | 2016-04-20 | H.J.亨氏公司 | Probiotic composition and method |
RU2485964C1 (en) * | 2012-01-10 | 2013-06-27 | Сергей Александрович Староверов | Immunostimulating composition for animals |
US20140037813A1 (en) * | 2012-08-02 | 2014-02-06 | Mead Johnson Nutrition Company | Nutritional creamer composition |
US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
EP2996487B1 (en) | 2013-03-08 | 2019-12-11 | Axiom Foods Inc. | Rice protein supplements |
BR112015028164B1 (en) | 2013-05-10 | 2022-02-08 | H.J. Heinz Company Brands Llc | USES OF THE PROBIOTIC BACTERIA, LACTOBACILLUS PARACASEI, TO TREAT A MICROBIAL INFECTION AND TO PREVENT OR REDUCE THE SEVERITY OF A MICROBIAL INFECTION |
AU2014369772A1 (en) * | 2013-12-20 | 2016-05-19 | Nestec S.A. | Nutritional compositions for reducing intestinal pathogens |
US20170056462A1 (en) * | 2014-04-25 | 2017-03-02 | Nexira International | Use of a composition comprising arabic gum (ag) for improving gut impermeability |
US20170274007A1 (en) * | 2014-09-23 | 2017-09-28 | Dom Terry International S.R.L. | Prebiotic inulin based preparation |
CN104432104A (en) * | 2014-11-05 | 2015-03-25 | 江南大学 | Preparation method of salty high-protein probiotic nutrition bar |
CN107072254A (en) | 2014-11-25 | 2017-08-18 | 雀巢产品技术援助有限公司 | For the method and composition for lifting lean body mass, minimizing body fat increase and management weight |
AU2015352099B2 (en) | 2014-11-25 | 2020-08-13 | Société des Produits Nestlé S.A. | Methods and compositions for preserving lean body mass and promoting fat loss during weight loss |
JP6334067B2 (en) | 2015-08-25 | 2018-05-30 | 株式会社日本触媒 | Cement additive, cement composition, and raw material for cement additive |
CN105661017A (en) * | 2016-02-03 | 2016-06-15 | 程雪娇 | Livestock feed and preparation method |
US9855305B2 (en) | 2016-03-29 | 2018-01-02 | Companion Therapeutics Llc | Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and prebiotics effective in preventing adverse effects associated with the use of proton-pump inhibitors |
CN110868870A (en) | 2017-05-12 | 2020-03-06 | 艾斯姆食品公司 | Rice products and systems and methods for making same |
MX2021004361A (en) | 2018-10-18 | 2021-05-28 | Hills Pet Nutrition Inc | Pet food compositions. |
CA3116822A1 (en) | 2018-12-13 | 2020-06-18 | Societe Des Produits Nestle Sa | Methods for enhancing metabolic health in an animal |
CN113163800A (en) | 2018-12-13 | 2021-07-23 | 雀巢产品有限公司 | Method for increasing fat oxidation or energy expenditure or satiety in an animal |
CN112912088A (en) | 2019-01-16 | 2021-06-04 | N·V·努特里奇亚 | Fermented formula food with non-digestible oligosaccharides for rotavirus-induced infections |
AU2020410289A1 (en) | 2019-12-19 | 2022-05-26 | Societe Des Produits Nestle Sa | Compositions and methods for providing a health benefit to a growing animal |
CN111329046A (en) * | 2020-03-13 | 2020-06-26 | 上海复旦奥医医学科技有限公司 | Special clinical nutrition formula for nasopharyngeal carcinoma and preparation method thereof |
MX2023002625A (en) | 2020-09-03 | 2023-03-17 | Nestle Sa | Compositions and methods for providing health benefits in an animal. |
EP4171540A1 (en) | 2020-09-04 | 2023-05-03 | Société des Produits Nestlé S.A. | Compositions and methods for providing health benefits in an animal |
CN116568151A (en) | 2020-12-11 | 2023-08-08 | 雀巢产品有限公司 | Compositions and methods for pet foods |
US20230165277A1 (en) | 2021-11-29 | 2023-06-01 | Société des Produits Nestlé S.A. | Methods and compositions for providing a health benefit in an animal |
US20230165281A1 (en) | 2021-11-29 | 2023-06-01 | Société des Produits Nestlé S.A. | Methods and compositions for providing a health benefit in an animal |
CN114848682A (en) * | 2022-03-11 | 2022-08-05 | 中南大学湘雅三医院 | Vitamin B6+ probiotic mixture and application thereof in preparation of medicines for relieving stress-related secondary injury and aseptic inflammation |
WO2024057113A1 (en) | 2022-09-13 | 2024-03-21 | Societe Des Produits Nestle Sa | Methods for providing and determining an efficacious weight loss diet for a canine |
WO2024057117A1 (en) | 2022-09-14 | 2024-03-21 | Societe Des Produits Nestle Sa | Compositions and methods utilizing southern ocean mackerel oil for providing health benefits in an animal |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54129163A (en) | 1978-03-28 | 1979-10-06 | Fujiya Kk | Production of instant yogurt powder |
DE3727946A1 (en) | 1987-08-21 | 1989-03-02 | Werner Georg Munk | RECONSTITUTABLE DRY PRODUCT FOR DIRECT CONSUMPTION, METHOD FOR THE PRODUCTION THEREOF AND ITS USE |
CH680192A5 (en) | 1989-12-13 | 1992-07-15 | Nestle Sa | |
JP3347381B2 (en) * | 1993-01-27 | 2002-11-20 | 協和醗酵工業株式会社 | Pet food |
US5565630A (en) | 1993-11-17 | 1996-10-15 | Monaghan Medical Corporation | Peak flow meter |
JP2973844B2 (en) | 1994-04-27 | 1999-11-08 | 不二製油株式会社 | Manufacturing method of cream cheese-like food |
JPH08126473A (en) * | 1994-09-08 | 1996-05-21 | Fuji Oil Co Ltd | Oily composition, its production and oily coated confectionery using the same |
US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
AUPN881396A0 (en) * | 1996-03-20 | 1996-04-18 | Arnott's Biscuits Limited | Enhancement of microbial colonization of the gastrointestinal tract |
DE69624805T3 (en) * | 1996-07-31 | 2007-01-04 | Raffinerie Tirlemontoise, S.A. | Fructan and / or polydextrose containing milk product powders; Process for their preparation and use thereof |
JP4065038B2 (en) | 1996-08-07 | 2008-03-19 | カルピス株式会社 | Computational workload stress relievers |
DE69802413T3 (en) * | 1997-07-05 | 2009-07-16 | Société des Produits Nestlé S.A. | LACTOBACILLI FOR INCREASING MINERAL ABSORPTION THROUGH DARM CELLS |
CN1208620A (en) * | 1997-08-15 | 1999-02-24 | 陈秀枢 | Composite contg. bacterium bifidum and lactobacillus |
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
US6093425A (en) * | 1997-11-21 | 2000-07-25 | Princeton Nutrition, L.L.C. | Complete nutritional milk compositions and products |
US6117477A (en) * | 1998-03-18 | 2000-09-12 | Kal Kan Foods, Inc. | Multicomponent food product and methods of making and using the same |
NZ510643A (en) * | 1998-08-21 | 2002-06-28 | Advanced Nutritional Foods Pty | Composition of calcium and an oligosaccharide |
EP1010374B2 (en) * | 1998-12-15 | 2009-07-29 | Societe Des Produits Nestle S.A. | Fibre blend for enteral composition |
CA2281463A1 (en) * | 1999-08-26 | 2001-02-26 | Stanley H. Zlotkin | Composition comprising micronutrients in combination with prebiotics, probiotics, and synbiotics |
GB2369777B (en) * | 2000-10-05 | 2004-10-27 | St Ivel Ltd | Food products with antimicrobial lactic acid bacteria |
GB0100273D0 (en) * | 2001-01-08 | 2001-02-14 | Nestle Sa | Nutritional composition for a bone condition |
-
2000
- 2000-11-14 GB GBGB0027761.6A patent/GB0027761D0/en not_active Ceased
-
2001
- 2001-11-14 PL PL362438A patent/PL201161B1/en not_active IP Right Cessation
- 2001-11-14 AT AT01996314T patent/ATE336909T1/en not_active IP Right Cessation
- 2001-11-14 CN CN2013100726216A patent/CN103181564A/en active Pending
- 2001-11-14 WO PCT/EP2001/013302 patent/WO2002039834A1/en active IP Right Grant
- 2001-11-14 UA UA2003065544A patent/UA78196C2/en unknown
- 2001-11-14 MX MXPA03004268A patent/MXPA03004268A/en active IP Right Grant
- 2001-11-14 BR BR0115311-0A patent/BR0115311A/en not_active Application Discontinuation
- 2001-11-14 EP EP01996314.9A patent/EP1339294B2/en not_active Expired - Lifetime
- 2001-11-14 AU AU2186002A patent/AU2186002A/en active Pending
- 2001-11-14 DE DE60122570.8T patent/DE60122570T3/en not_active Expired - Lifetime
- 2001-11-14 IL IL15567401A patent/IL155674A/en not_active IP Right Cessation
- 2001-11-14 CA CA2427385A patent/CA2427385C/en not_active Expired - Lifetime
- 2001-11-14 ES ES01996314.9T patent/ES2269514T5/en not_active Expired - Lifetime
- 2001-11-14 KR KR10-2003-7006389A patent/KR20030051802A/en not_active Application Discontinuation
- 2001-11-14 AU AU2002221860A patent/AU2002221860B2/en not_active Ceased
- 2001-11-14 RU RU2003117436/13A patent/RU2289955C2/en not_active IP Right Cessation
- 2001-11-14 CN CNA018188958A patent/CN1503632A/en active Pending
- 2001-11-14 JP JP2002542219A patent/JP2004513898A/en active Pending
-
2003
- 2003-05-12 NO NO20032129A patent/NO326348B1/en not_active IP Right Cessation
- 2003-05-13 US US10/436,477 patent/US6929793B2/en not_active Expired - Lifetime
- 2003-06-12 ZA ZA200304605A patent/ZA200304605B/en unknown
-
2005
- 2005-05-19 US US11/133,588 patent/US20050208035A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101388395B1 (en) * | 2008-01-10 | 2014-04-22 | 뉴트리 가부시키가이샤 | Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of elderly |
CN103478716A (en) * | 2013-09-23 | 2014-01-01 | 南昌大学 | Preparation method for functional food with immunity enhancing effect |
Also Published As
Publication number | Publication date |
---|---|
IL155674A0 (en) | 2003-11-23 |
ATE336909T1 (en) | 2006-09-15 |
BR0115311A (en) | 2004-01-06 |
NO20032129D0 (en) | 2003-05-12 |
CA2427385C (en) | 2010-05-04 |
DE60122570D1 (en) | 2006-10-05 |
EP1339294B1 (en) | 2006-08-23 |
ZA200304605B (en) | 2004-09-13 |
PL201161B1 (en) | 2009-03-31 |
ES2269514T3 (en) | 2007-04-01 |
NO20032129L (en) | 2003-07-11 |
MXPA03004268A (en) | 2004-04-21 |
CA2427385A1 (en) | 2002-05-23 |
IL155674A (en) | 2005-07-25 |
RU2289955C2 (en) | 2006-12-27 |
US6929793B2 (en) | 2005-08-16 |
US20050208035A1 (en) | 2005-09-22 |
PL362438A1 (en) | 2004-11-02 |
DE60122570T3 (en) | 2015-05-21 |
JP2004513898A (en) | 2004-05-13 |
CN1503632A (en) | 2004-06-09 |
DE60122570T2 (en) | 2007-09-20 |
AU2186002A (en) | 2002-05-27 |
EP1339294B2 (en) | 2015-01-21 |
US20040005305A1 (en) | 2004-01-08 |
UA78196C2 (en) | 2007-03-15 |
WO2002039834A1 (en) | 2002-05-23 |
CN103181564A (en) | 2013-07-03 |
ES2269514T5 (en) | 2015-04-01 |
AU2002221860B2 (en) | 2006-08-10 |
GB0027761D0 (en) | 2000-12-27 |
NO326348B1 (en) | 2008-11-17 |
EP1339294A1 (en) | 2003-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6929793B2 (en) | Nutritional composition for treating an immune condition | |
AU2002221860A1 (en) | Nutritional composition for an immune condition | |
EP1841330B1 (en) | Use of infant formula with reduced protein content | |
EP0745333B1 (en) | Nutritional compositions in various forms | |
EP2645883B1 (en) | Staged infant feeding regimen to promote healthy development and growth | |
MX2011003179A (en) | Nutritional composition to promote healthy development and growth. | |
US20080274127A1 (en) | Amino acid supplementation for a healthy microbiota ecosystem | |
EP1351584A2 (en) | Nutritional composition for a bone condition | |
AU2011100142A4 (en) | Infant Formula: Probiotic Supplementation | |
JP2019081733A5 (en) | ||
Lloyd | US whey products and child nutrition | |
JPH1146720A (en) | Nutritive composition for promoting absorption of calcium | |
Singh | DAIRY NUTRACEUTICALS AND FUNCTIONAL DAIRY FOODS: CURRENT STATUS, ISSUES AND CHALLENGES | |
IES970234A2 (en) | Food Product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |